Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 19, 2026, 4:45 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1153–1176 of 2,737 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Neuroendocrine Tumours Clear all
Completed Phase 2 Interventional Results available

Prospective Randomized Study of Cell Transfer Therapy for Metastatic Melanoma Using Tumor Infiltrating Lymphocytes Plus IL-2 Following Non-Myeloablative Lymphocyte Depleting Chemo Regimen Alone or in Conjunction With 12Gy Total Body Irradiation (TBI...

NCT01319565
View directory record Official record
Conditions
Metastatic Melanoma, Skin Cancer
Interventions
Aldesleukin, Cyclophosphamide, Fludarabine, Young TIL, Total Body Irradiation (TBI)
Drug · Biological · Radiation
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years to 66 Years
Enrollment
102 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2024
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Dec 19, 2025 · Synced Oct 19, 2026, 4:45 PM EDT
Completed Not applicable Interventional

Assessing Patient Anxiety During Mohs Micrographic Surgery

NCT03756792
View directory record Official record
Conditions
Anxiety
Interventions
Normal Education Material, Vignette
Behavioral
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
18 Years to 80 Years
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2024
U.S. locations
1
States / cities
Winston-Salem, North Carolina
Source: ClinicalTrials.gov public record
Updated Jan 29, 2026 · Synced Oct 19, 2026, 4:45 PM EDT
Terminated Phase 3 Interventional

Elesclomol (STA-4783) With Paclitaxel Versus Paclitaxel Alone in Melanoma

NCT00522834
View directory record Official record
Conditions
Melanoma
Interventions
Elesclomol (STA-4783), Paclitaxel
Drug
Lead sponsor
Synta Pharmaceuticals Corp.
Industry
Eligibility
18 Years and older
Enrollment
630 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
61
States / cities
Tucson, Arizona • Little Rock, Arkansas • La Jolla, California + 50 more
Source: ClinicalTrials.gov public record
Updated Mar 4, 2014 · Synced Oct 19, 2026, 4:45 PM EDT
Terminated Phase 2 Interventional

Apalutamide, Abiraterone Acetate, and Prednisone in Treating Participants With Metastatic Castration Resistant Prostate Cancer

NCT03360721
View directory record Official record
Conditions
Castration-Resistant Prostate Carcinoma, Prostate Adenocarcinoma Without Neuroendocrine Differentiation, Stage IV Prostate Cancer AJCC v8, Stage IVA Prostate Cancer AJCC v8, Stage IVB Prostate Cancer AJCC v8
Interventions
Abiraterone Acetate, Apalutamide, Prednisone
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older · Male only
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2026
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Mar 16, 2026 · Synced Oct 19, 2026, 4:45 PM EDT
Active, not recruiting Phase 1 Interventional

A Study of TSR-022 in Participants With Advanced Solid Tumors (AMBER)

NCT02817633
View directory record Official record
Conditions
Neoplasms
Interventions
TSR-022, Nivolumab, TSR-042, TSR-033, Docetaxel, Pemetrexed, Cisplatin, Carboplatin
Drug
Lead sponsor
Tesaro, Inc.
Industry
Eligibility
18 Years and older
Enrollment
463 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2027
U.S. locations
64
States / cities
Goodyear, Arizona • Scottsdale, Arizona • Tucson, Arizona + 56 more
Source: ClinicalTrials.gov public record
Updated Oct 28, 2025 · Synced Oct 19, 2026, 4:45 PM EDT
Recruiting Phase 2 Interventional

A Study on How to Safely Guide Surgery for Melanoma and Similar Skin Tumors in Children Using Pathology and Genetic Information

NCT07621614
View directory record Official record
Conditions
Clinical Stage 0 Cutaneous Melanoma AJCC v8, Clinical Stage I Cutaneous Melanoma AJCC v8, Clinical Stage II Cutaneous Melanoma AJCC v8, Cutaneous Melanocytic Neoplasm, Cutaneous Melanoma, Cutaneous Spitz Melanocytoma, Cutaneous Spitz Melanoma
Interventions
Biospecimen Collection, Chest Radiography, Computed Tomography, Fludeoxyglucose F-18, Magnetic Resonance Imaging, Patient Observation, Positron Emission Tomography, Re-Excision, Sentinel Lymph Node Biopsy, Ultrasound Imaging, Wide Local Excision
Procedure · Other
Lead sponsor
Children's Oncology Group
Network
Eligibility
Up to 25 Years
Enrollment
51 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2027 – 2028
U.S. locations
13
States / cities
Oakland, California • Wilmington, Delaware • Jacksonville, Florida + 10 more
Source: ClinicalTrials.gov public record
Updated Sep 24, 2026 · Synced Oct 19, 2026, 4:45 PM EDT
Completed Phase 1 Interventional

Tremelimumab and CP-870,893 in Patients With Metastatic Melanoma

NCT01103635
View directory record Official record
Conditions
Recurrent Melanoma, Stage IV Melanoma
Interventions
CD40 agonist monoclonal antibody CP-870,893, tremelimumab, laboratory biomarker analysis
Biological · Other
Lead sponsor
Abramson Cancer Center at Penn Medicine
Other
Eligibility
18 Years and older
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2016
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Apr 7, 2020 · Synced Oct 19, 2026, 4:45 PM EDT
Terminated Phase 3 Interventional Results available

Pembrolizumab With Talimogene Laherparepvec or Placebo in Unresected Melanoma

NCT02263508
View directory record Official record
Conditions
Melanoma
Interventions
Talimogene Laherparepvec, Pembrolizumab, Placebo
Drug
Lead sponsor
Amgen
Industry
Eligibility
18 Years to 95 Years
Enrollment
713 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2021
U.S. locations
41
States / cities
Birmingham, Alabama • Mobile, Alabama • Beverly Hills, California + 32 more
Source: ClinicalTrials.gov public record
Updated Nov 14, 2022 · Synced Oct 19, 2026, 4:45 PM EDT
Withdrawn Phase 2 Interventional

SBRT as a Vaccination for Metastatic Melanoma

NCT04042506
View directory record Official record
Conditions
Metastatic Melanoma
Interventions
Nivolumab 10 MG/ML Intravenous Solution [OPDIVO], Stereotactic Body Radiation Therapy (SBRT)
Drug · Radiation
Lead sponsor
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
2
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Apr 12, 2021 · Synced Oct 19, 2026, 4:45 PM EDT
Completed Phase 1 Interventional

A Study of BIND-014 Given to Patients With Advanced or Metastatic Cancer

NCT01300533
View directory record Official record
Conditions
Metastatic Cancer, Cancer, Solid Tumors
Interventions
BIND-014
Drug
Lead sponsor
BIND Therapeutics
Industry
Eligibility
18 Years and older
Enrollment
58 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2016
U.S. locations
6
States / cities
Scottsdale, Arizona • Greenbrae, California • Los Angeles, California + 3 more
Source: ClinicalTrials.gov public record
Updated Feb 9, 2016 · Synced Oct 19, 2026, 4:45 PM EDT
Terminated Phase 1 Interventional

A Phase I Study of LXS196 in Patients With Metastatic Uveal Melanoma.

NCT02601378
View directory record Official record
Conditions
Uveal Melanoma
Interventions
LXS196, LXS196 and HDM201
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
107 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2022
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Sep 29, 2022 · Synced Oct 19, 2026, 4:45 PM EDT
Recruiting Phase 1 Interventional

Study of CRX100 as Monotherapy and in Combination With Pembrolizumab in Patients With Advanced Solid Malignancies

NCT04282044
View directory record Official record
Conditions
Solid Tumor, Adult, Triple Negative Breast Cancer, Colorectal Cancer, Hepatocellular Carcinoma, Osteosarcoma, Epithelial Ovarian Cancer, Gastric Cancer, Non-small Cell Lung Cancer, Malignant Melanoma
Interventions
CRX100 suspension for infusion, Fludarabine, Cyclophosphamide
Biological · Combination Product
Lead sponsor
BioEclipse Therapeutics
Industry
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2026
U.S. locations
3
States / cities
Scottsdale, Arizona • La Jolla, California • Stanford, California
Source: ClinicalTrials.gov public record
Updated Feb 8, 2024 · Synced Oct 19, 2026, 4:45 PM EDT
Recruiting No phase listed Observational

Assessing Benefits and Harms of Cannabis/Cannabinoid Use Among Cancer Patients Treated in Community Oncology Clinics

NCT06418204
View directory record Official record
Conditions
Breast Carcinoma, Colorectal Carcinoma, Lung Non-Small Cell Carcinoma, Melanoma, Non-Hodgkin Lymphoma
Interventions
Non-interventional Study
Other
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
18 Years and older
Enrollment
2,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
483
States / cities
Fairbanks, Alaska • Kingman, Arizona • Phoenix, Arizona + 376 more
Source: ClinicalTrials.gov public record
Updated Oct 7, 2026 · Synced Oct 19, 2026, 4:45 PM EDT
Completed Phase 2 Interventional Results available

Tumor and Vaccine Site With a Toll Like Receptor (TLR) Agonist

NCT00960752
View directory record Official record
Conditions
Melanoma
Interventions
gp100, R848 gel, MAGE-3
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
47 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2020
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Aug 13, 2021 · Synced Oct 19, 2026, 4:45 PM EDT
Completed Not applicable Interventional Results available

Adaptive Staged Stereotactic Body Radiation Therapy in Treating Patients With Spinal Metastases That Cannot Be Removed by Surgery

NCT02527304
View directory record Official record
Conditions
Melanoma, Metastatic Malignant Neoplasm in the Spine, Renal Cell Carcinoma, Soft Tissue Sarcoma, Spinal Cord Compression
Interventions
Image-Guided Adaptive Radiation Therapy, Quality-of-Life Assessment, Questionnaire Administration, Stereotactic Body Radiation Therapy
Radiation · Other
Lead sponsor
Albert Einstein College of Medicine
Other
Eligibility
18 Years and older
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
1
States / cities
The Bronx, New York
Source: ClinicalTrials.gov public record
Updated Mar 6, 2024 · Synced Oct 19, 2026, 4:45 PM EDT
Completed Phase 2 Interventional

Lifileucel With Reduced Dose Fludarabine/Cyclophosphamide Lymphodepletion and Interleukin-2 for the Treatment of Patients With Unresectable or Metastatic Melanoma

NCT06151847
View directory record Official record
Conditions
Clinical Stage IV Cutaneous Melanoma AJCC v8, Metastatic Melanoma, Pathologic Stage IIIC Cutaneous Melanoma AJCC v8, Unresectable Melanoma
Interventions
Biospecimen Collection, Cyclophosphamide, Echocardiography, Fludarabine, Interleukin-2, Lifileucel, Magnetic Resonance Imaging, Multigated Acquisition Scan, Tumor Resection
Procedure · Drug · Biological
Lead sponsor
University of Kansas Medical Center
Other
Eligibility
18 Years to 70 Years
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
1
States / cities
Kansas City, Kansas
Source: ClinicalTrials.gov public record
Updated Apr 30, 2026 · Synced Oct 19, 2026, 4:45 PM EDT
Completed Phase 1Phase 2 Interventional

Combined Modality Treatment for Patients With Stage IV Melanoma

NCT00313235
View directory record Official record
Conditions
Malignant Melanoma Stage IV
Interventions
DC Vaccine and Cyclophosphamide
Biological
Lead sponsor
Baylor Research Institute
Other
Eligibility
21 Years to 75 Years
Enrollment
41 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2012
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Jun 13, 2013 · Synced Oct 19, 2026, 4:45 PM EDT
Active, not recruiting Phase 2 Interventional Results available

Study to Evaluate Safety and Dosimetry of Lutathera in Adolescent Patients With GEP-NETs and PPGLs

NCT04711135
View directory record Official record
Conditions
Gastroenteropancreatic Neuroendocrine Tumors, Pheochromocytoma, Paraganglioma
Interventions
Lutetium [177Lu] oxodotreotide/dotatate
Drug
Lead sponsor
Advanced Accelerator Applications
Industry
Eligibility
12 Years to 17 Years
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2034
U.S. locations
3
States / cities
Lexington, Kentucky • Cincinnati, Ohio • Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Feb 12, 2026 · Synced Oct 19, 2026, 4:45 PM EDT
Recruiting Phase 1Phase 2 Interventional

Intratumoral N17350 in Advanced Solid Tumors

NCT07339176
View directory record Official record
Conditions
Neoplasms, Solid Tumor, Breast Neoplasms, Triple-Negative, Squamous Cell Carcinoma of Skin, Melanoma, Head and Neck Neoplasms, Carcinoma, Squamous Cell, Carcinoma, Non-Small-Cell Lung
Interventions
N17350
Biological
Lead sponsor
Onchilles Pharma Inc
Industry
Eligibility
18 Years and older
Enrollment
275 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
6
States / cities
Los Angeles, California • San Diego, California • San Francisco, California + 2 more
Source: ClinicalTrials.gov public record
Updated Sep 23, 2026 · Synced Oct 19, 2026, 4:45 PM EDT
Completed Phase 2 Interventional Results available

Efficacy Study of Pharmacokinetic(PK)/Pharmacodynamic(PD) Relationship of Monotherapy MORAb-004 in Metastatic Melanoma

NCT01335009
View directory record Official record
Conditions
Metastatic Melanoma
Interventions
MORAb-004 (monoclonal antibody)
Biological
Lead sponsor
Eisai Inc.
Industry
Eligibility
18 Years and older
Enrollment
76 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2020
U.S. locations
20
States / cities
Scottsdale, Arizona • Los Angeles, California • Aurora, Colorado + 14 more
Source: ClinicalTrials.gov public record
Updated Sep 1, 2021 · Synced Oct 19, 2026, 4:45 PM EDT
Completed Phase 1 Interventional Results available

A Phase 1 Study of Pegilodecakin (LY3500518) in Participants With Advanced Solid Tumors

NCT02009449
View directory record Official record
Conditions
Melanoma, Prostate Cancer, Ovarian Cancer, Renal Cell Carcinoma, Colorectal Carcinoma, Pancreatic Carcinoma, Non-small Cell Lung Carcinoma, Solid Tumors, Breast Cancer
Interventions
Pegilodecakin, Paclitaxel or Docetaxel and Carboplatin or Cisplatin, FOLFOX (Oxaliplatin/Leucovorin/5-Fluorouracil), gemcitabine/nab-paclitaxel, Capecitabine, Pazopanib, Pembrolizumab, Paclitaxel, nivolumab, Gemcitabine/carboplatin
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older
Enrollment
353 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2023
U.S. locations
10
States / cities
Los Angeles, California • San Francisco, California • Denver, Colorado + 7 more
Source: ClinicalTrials.gov public record
Updated Jul 9, 2026 · Synced Oct 19, 2026, 4:45 PM EDT
Completed Phase 1Phase 2 Interventional

Vaccine Therapy in Treating Patients With Stage IV or Recurrent Malignant Melanoma

NCT00039325
View directory record Official record
Conditions
Melanoma (Skin)
Interventions
dendritic cell-MART-1 peptide vaccine
Biological
Lead sponsor
Jonsson Comprehensive Cancer Center
Other
Eligibility
18 Years and older
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2009
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Aug 3, 2020 · Synced Oct 19, 2026, 4:45 PM EDT
Terminated Phase 1Phase 2 Interventional Results available

REVEAL Study of NKTR-262 in Combination With NKTR-214 and Nivolumab in Patients With Locally Advanced / Metastatic Solid Tumor Malignancies

NCT03435640
View directory record Official record
Conditions
Melanoma, Merkel Cell Carcinoma, Triple Negative Breast Cancer, Head and Neck Squamous Cell Carcinoma, Renal Cell Carcinoma, Colorectal Cancer, Sarcoma
Interventions
NKTR-262, bempegaldesleukin, nivolumab
Drug
Lead sponsor
Nektar Therapeutics
Industry
Eligibility
18 Years and older
Enrollment
64 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2022
U.S. locations
14
States / cities
Scottsdale, Arizona • La Jolla, California • Tampa, Florida + 11 more
Source: ClinicalTrials.gov public record
Updated Mar 8, 2023 · Synced Oct 19, 2026, 4:45 PM EDT
Completed Phase 2 Interventional

Vaccine Therapy and Interleukin-12 With Either Alum or Sargramostim After Surgery in Treating Patients With Melanoma

NCT00031733
View directory record Official record
Conditions
Intraocular Melanoma, Melanoma (Skin)
Interventions
MART-1 antigen, gp100 antigen, incomplete Freund's adjuvant, recombinant interleukin-12, sargramostim, tyrosinase peptide, alum adjuvant, adjuvant therapy
Biological · Drug · Procedure
Lead sponsor
University of Southern California
Other
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2007
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated May 22, 2014 · Synced Oct 19, 2026, 4:45 PM EDT